MarketLine  

All articles by MarketLine  

1. Can BMS make a success of its Celgene acquisition?

   Pharmaceutical company Bristol-Myers Squibb (BMS) has bought US biotech Celgene for $74bn as it seeks to leave its troubles behind….
   Read More…

   10 Jan